394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
Tarantino P, Kim S, Chan N, Hughes M, Smith K, D’Amico O, Kusmick R, Pereslete A, Alder L, Anders C, Morganti S, Garrido-Castro A, Lorusso P, Lustberg M, Sammons S, Lin N, Li T, Tayob N, Rimm D, Tolaney S. 394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC). Annals Of Oncology 2024, 35: s384-s385. DOI: 10.1016/j.annonc.2024.08.342.Peer-Reviewed Original ResearchQuantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay
Liu M, Vathiotis I, Robbins C, Chan N, Moutafi M, Burela S, Xirou V, Schalper K, Herbst R, Syrigos K, Rimm D. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay. Modern Pathology 2024, 37: 100556. PMID: 38964502, PMCID: PMC11416319, DOI: 10.1016/j.modpat.2024.100556.Peer-Reviewed Original ResearchNon-small cell lung cancerCases of non-small cell lung cancerNon-small cell lung cancer casesT-DXdCell lung cancerHER2 expressionBreast cancerRare case of non-small cell lung cancerQuantitative immunofluorescenceAntibody-drug conjugate trastuzumab deruxtecanLung cancerHER2 antibody-drug conjugatesNon-small cell lung cancer patientsDetecting HER2 expressionHER2-targeted therapyMetastatic breast cancerHER2 protein expressionBreast cancer casesHER2 protein levelsAntibody-drug conjugatesProportion of casesTrastuzumab deruxtecanNSCLC casesFrequency of casesImmunohistochemistry scoreAbstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
Tarantino P, Hughes M, Kusmick R, Alder L, Pereslete A, Noteware L, Moore H, Van Swearingen A, Li T, Gupta H, Smith K, Morganti S, Files J, Sendrick K, Buck S, Dillon D, Jeselsohn R, Li Y, Cherniack A, Prat A, Chan N, Rimm D, Curigliano G, Sammons S, Anders C, Lin N, Tolaney S. Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE). Cancer Research 2024, 84: ps08-09-ps08-09. DOI: 10.1158/1538-7445.sabcs23-ps08-09.Peer-Reviewed Original ResearchMetastatic breast cancerHER2+ diseaseHER2-lowHER2-low diseaseT-DXdActivity of trastuzumabHER2 statusHER2+Overall survivalHER2-0Breast cancerMetastatic diagnosisPrimary tumorFollow-upHormone receptor (HR)-positive tumorsHistory of brain metastasesHER2-low expressionHER2-low statusHER2-negative casesHER2-negative tumorsMedian follow-upArchival tumor samplesDana-Farber Cancer InstituteInterstitial lung diseaseImpact outcomes